Largest Real-World Study Confirms Maternal RSV Vaccination Reduces Infant Hospitalization Risk by Over 80%

Major UKHSA study of 290,000 infants confirms maternal RSV shots are 81.3% effective. Learn how early third-trimester vaccination protects vulnerable newborns.

By: AXL Media

Published: Apr 18, 2026, 11:08 AM EDT

Source: Information for this report was sourced from EurekAlert

National Immunization Initiative Demonstrates Rapid Public Health Impact

Following the introduction of the national maternal respiratory syncytial virus (RSV) vaccination program in England on September 1, 2024, new clinical data suggests the initiative has profoundly altered the landscape of infant healthcare. By offering the Bivalent Prefusion F vaccine to pregnant women starting at 28 weeks’ gestation, health officials have targeted the leading cause of infant hospitalization worldwide. The results of the retrospective cohort study, which captured approximately 90% of all births in England during the study period, provide the most robust evidence to date that maternal immunization is a highly effective tool for preventing severe lower respiratory tract infections in newborns.

Statistical Disparity Highlights High Efficacy Among Vaccinated Cohorts

The analysis of 289,399 infants born between late 2024 and early 2025 revealed a stark contrast in medical outcomes based on maternal vaccination status. Of the 4,594 RSV-associated hospitalizations recorded, infants born to unvaccinated mothers accounted for an overwhelming 87.2% of cases, despite making up only 55% of the total study population. This data underscores the vaccine's role in mitigating severe illness, with overall effectiveness estimated at 81.3%. According to Matt Wilson, an epidemiologist at the UK Health Security Agency, the sheer scale of the study provides definitive proof of the vaccine's ability to shield infants from bronchiolitis and pneumonia.

Temporal Window of Administration Key to Optimal Protection

The study identified a critical relationship between the timing of the injection and the level of immunity transferred to the infant. While effectiveness reaches its peak of nearly 85% when the vaccine is administered at least four weeks before delivery, meaningful protection begins to manifest much sooner. Wilson noted that even infants born just 10 to 13 days after maternal vaccination saw a 50% reduction in hospital admissions compared to those in the unvaccinated group. However, the data also showed that vaccination less than 10 days before birth resulted in no measurable reduction in risk, emphasizing the need for early intervention within the recommended third-trimester window.